360 related articles for article (PubMed ID: 31766279)
1. Biological Background of Resistance to Current Standards of Care in Multiple Myeloma.
Mogollón P; Díaz-Tejedor A; Algarín EM; Paíno T; Garayoa M; Ocio EM
Cells; 2019 Nov; 8(11):. PubMed ID: 31766279
[TBL] [Abstract][Full Text] [Related]
2. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms in multiple myeloma drug resistance.
Nikesitch N; Ling SC
J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
[TBL] [Abstract][Full Text] [Related]
4. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.
Harding T; Baughn L; Kumar S; Van Ness B
Leukemia; 2019 Apr; 33(4):863-883. PubMed ID: 30683909
[TBL] [Abstract][Full Text] [Related]
5. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
6. The power of proteasome inhibition in multiple myeloma.
Guerrero-Garcia TA; Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Mitsiades C; Anderson KC; Richardson PG
Expert Rev Proteomics; 2018 Dec; 15(12):1033-1052. PubMed ID: 30427223
[TBL] [Abstract][Full Text] [Related]
7. Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C; Maglio M; Ghobrial IM; Richardson PG
Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Noonan K; Colson K
Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
[TBL] [Abstract][Full Text] [Related]
9. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
10. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E
Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151
[TBL] [Abstract][Full Text] [Related]
12. New Targets and New Agents in High-Risk Multiple Myeloma.
Nooka AK; Lonial S
Am Soc Clin Oncol Educ Book; 2016; 35():e431-41. PubMed ID: 27249751
[TBL] [Abstract][Full Text] [Related]
13. [Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
Gu LF; Cui XG; Cao XM; Chen SP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):608-612. PubMed ID: 28446321
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
15. Roles of noncoding RNAs in drug resistance in multiple myeloma.
Li J; Zou J; Wan X; Sun C; Chu Z; Hu Y
J Cell Physiol; 2020 Nov; 235(11):7681-7695. PubMed ID: 32324301
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Baertsch MA; Hundemer M; Hillengass J; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):258-261. PubMed ID: 28840598
[TBL] [Abstract][Full Text] [Related]
17. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of clonal evolution in multiple myeloma.
Furukawa Y; Kikuchi J
Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
[TBL] [Abstract][Full Text] [Related]
19. [Towards precision medicine in myeloma: new evidence and challenges].
González-Calle V; Fonseca R
Medicina (B Aires); 2017; 77(3):222-226. PubMed ID: 28643680
[TBL] [Abstract][Full Text] [Related]
20. [Novel targeted therapy in multiple myeloma].
Izumi T
Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]